| Basics |
Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.
|
| IPO Date: |
March 16, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$7.77B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.38 | 2.14%
|
| Avg Daily Range (30 D): |
$0.95 | 1.32%
|
| Avg Daily Range (90 D): |
$0.80 | 1.23%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.96M |
| Avg Daily Volume (30 D): |
1.62M |
| Avg Daily Volume (90 D): |
1.6M |
| Trade Size |
| Avg Trade Size (Sh.): |
106 |
| Avg Trade Size (Sh.) (30 D): |
54 |
| Avg Trade Size (Sh.) (90 D): |
56 |
| Institutional Trades |
| Total Inst.Trades: |
9,614 |
| Avg Inst. Trade: |
$2.91M |
| Avg Inst. Trade (30 D): |
$5.66M |
| Avg Inst. Trade (90 D): |
$5.63M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.7M |
| Avg Closing Trade (30 D): |
$27.9M |
| Avg Closing Trade (90 D): |
$25.12M |
| Avg Closing Volume: |
160.08K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$4.48
|
$1.36
|
$.96
|
|
Diluted EPS
|
$4.37
|
$1.33
|
$.93
|
|
Revenue
|
$ 1.18B
|
$ 325.72M
|
$ 264.86M
|
|
Gross Profit
|
$ 992.43M
|
$ 279.36M
|
$ 216.46M
|
|
Net Income / Loss
|
$ 557.28M
|
$ 165.16M
|
$ 118.1M
|
|
Operating Income / Loss
|
$ 682.67M
|
$ 202.44M
|
$ 141.54M
|
|
Cost of Revenue
|
$ 186.24M
|
$ 46.36M
|
$ 48.4M
|
|
Net Cash Flow
|
$ -126M
|
$ -114.47M
|
$ 60.48M
|
|
PE Ratio
|
14.85
|
|
|
|
|
|
